Austedo's drug class is a vmat2 inhibitor (vesicular monoamine transporter 2 inhibitor) What is tardive dyskinesia (td) and chorea associated with huntington’s disease The most common adverse reactions for austedo (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. She added, “these data articulate patient experience and further validate clinical research showing how austedo or austedo xr can help people living with tardive dyskinesia improve their symptoms while maintaining their mental health, something we care deeply about in our mission at teva to improve the lives of patients.” Austedo standard and xr tablets are currently indicated for adults for the treatment of chorea in huntington disease and tardive dyskinesia Austedo is the first vmat2 inhibitor approved by the us food and drug administration for adults with tardive dyskinesia
3 it is not currently approved for pediatric patients The fda has approved austedo xr in four new tablet strengths for adults diagnosed with tardive dyskinesia and chorea associated with huntington’s disease, according to the manufacturer
OPEN
